What is the present valuation and projected CAGR of the attention deficit hyperactivity disorder market?
The attention deficit hyperactivity disorder market size has grown strongly in recent years. It will grow from $16.29 billion in 2024 to $17.43 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to rising prevalence of ADHD, growing incidence of ADHD in children, and increasing awareness of ADHD, increasing healthcare expenditure, government initiatives for mental health awareness.
The attention deficit hyperactivity disorder market size is expected to see strong growth in the next few years. It will grow to $22.59 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing pediatric and adult patient populations receiving treatment, advanced healthcare infrastructure, growing adoption of personalized medicine, growing acceptance of mental health issues, and rising use of additives and preservatives in children’s diet. Major trends in the forecast period include improvements in technology and innovative treatments, advancements in diagnostic and treatment methods, development of new therapeutic agents, shift towards non-stimulant medications, and advancements in pharmaceutical treatments.
Get Your Free Sample of The Global Attention Deficit Hyperactivity Disorder Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21108&type=smp
What key drivers have fueled the attention deficit hyperactivity disorder market’s development over the years?
The growing adoption of personalized medicine is expected to propel the growth of the attention deficit hyperactivity disorder (ADHD) market going forward. Personalized medicine is a medical approach that tailors’ treatments to an individual’s genetic, environmental, and lifestyle factors for more precise and effective healthcare. The adoption of personalized medicine is attributed to advancements in genomic technologies, which enable the tailoring of treatments based on an individual’s genetic profile, leading to more effective and targeted therapies. Attention deficit hyperactivity disorder (ADHD) contributes significantly to personalized medicine by facilitating customized treatment strategies that consider an individual’s unique genetic, environmental, and behavioral characteristics, resulting in more effective and targeted interventions. For instance, in February 2024, according to a report published by the Personalized Medicine Coalition (PMC), a US-based non-profit organization, in 2023, personalized medicines accounted for over a third of new FDA drug approvals for the fourth consecutive year. The FDA approved 16 new personalized treatments for rare diseases (up from 6 in 2022), 7 cancer drugs, and 3 for other conditions. Therefore, the growing adoption of personalized medicine is driving the growth of the attention deficit hyperactivity disorder market.
What is the segmentation for the attention deficit hyperactivity disorder market?
The attention deficit hyperactivity disorder market covered in this report is segmented –
1) By Type: Stimulants, Non-Stimulants
2) By Age Group: Children, Adults
3) By Gender: Male, Female
4) By Dosage Form: Tablets, Capsules, Other Dosage Forms
5) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy
Subsegments:
1) By Stimulants: Methylphenidate-based Medications, Amphetamine-based Medications, Mixed Amphetamine Salts, Dexmethylphenidate
2) By Non-Stimulants: Atomoxetine (Strattera), Guanfacine (Intuniv), Clonidine (Kapvay), Bupropion (Wellbutrin)
Order your report now for swift delivery
Who are the most influential companies in the attention deficit hyperactivity disorder market?
Major companies operating in the attention deficit hyperactivity disorder market are Pfizer Inc., Johnson & Johnson, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Supernus Pharmaceuticals Inc., Neos Therapeutics Inc., Collegium Pharmaceutical Inc., Mallinckrodt Pharmaceuticals plc, Tris Pharma Inc., Arbor Pharmaceuticals LLC, Akili Interactive Labs Inc., Mind Medicine (MindMed) Inc., NeuroSigma Inc., KemPharm Inc., RespireRx Pharmaceuticals Inc., Cingulate Therapeutics LLC, Adlon Therapeutics L.P.
What are the top industry trends projected to impact the attention deficit hyperactivity disorder market?
Major companies operating in the attention deficit hyperactivity disorder (ADHD) market are focusing on developing innovative drugs, such as extended-release tablets, to improve treatment efficacy, enhance patient compliance, and provide long-lasting symptom control. Extended-release tablets are designed to release medication gradually over time, providing consistent symptom control throughout the day with a single dose, which reduces the need for multiple doses and improves convenience and adherence to the treatment plan for individuals with attention deficit hyperactivity disorder (ADHD). For instance, in February 2022, JAMP Pharma Group, a Canada-based pharmaceutical company, launched Guanfacine XR, a generic form of Takeda Canada Inc.’s INTUNIV XR, a branded medication intended to treat attention deficit hyperactivity disorder (ADHD). It is a long-acting form of guanfacine, which works by affecting certain receptors in the brain to improve attention, impulse control, and hyperactivity. The drug is available in multiple strengths (1 mg, 2 mg, 3 mg, and 4 mg) and comes in a 100-count bottle, providing flexibility for treatment.
What are the major regional insights for the attention deficit hyperactivity disorder market, and which region holds the top position?
North America was the largest region in the attention deficit hyperactivity disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Attention Deficit Hyperactivity Disorder Market Report 2025 Offer?
The attention deficit hyperactivity disorder market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition characterized by persistent inattention, hyperactivity, and impulsivity that interfere with daily functioning. It begins in childhood and can continue into adulthood, affecting focus, self-control, and organization. Treatment may include behavioral therapy, medication, and lifestyle adjustments.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21108
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
